Krishna Institute of Medical Sciences Limited (KIMS Hospitals) announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors also approved the merger of a wholly-owned subsidiary, KIMS Hospitals Private Limited, with the holding company. Additionally, the reappointment of key management personnel, including the Director & CEO and Chairman & Managing Director, for a further term of 5 years was approved.
KIMS Hospitals Announces Q2 Financial Performance and Strategic Approvals
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has disclosed its unaudited financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors, in a meeting held on November 4, 2026, reviewed and approved these financial statements, along with the limited review reports from statutory auditors.
Key Board Approvals
The Board also gave its nod to several strategic initiatives:
- Merger of Wholly-Owned Subsidiary: Approval was granted for the merger of KIMS Hospitals Private Limited (Transferor Company) with its Holding Company, Krishna Institute of Medical Sciences Limited (Transferee Company).
- O&M Agreement: The Board approved entering into transaction documents for an Operations and Management (O&M) Agreement between KIMS Swastha Private Limited and LOVR Institute of Medical Sciences Limited for Westfort Hospital, Thrissur.
- Reappointments: Based on recommendations from the Nomination and Remuneration Committee, the Board approved the reappointment of key leadership personnel for a further term of 5 years. This includes Dr. Abhinay Bollineni as Director & CEO and Dr. Bhaskara Rao Bollineni as Chairman & Managing Director, with the latter continuing beyond the age of 70. Ms. Dandamudi Anitha was also reappointed as Whole-time Director for a 5-year term.
Financial Results Availability
The unaudited financial results, along with the limited review reports, are available on the company’s website (www.kimshospitals.com/investors/Disclosures) and the websites of the BSE and NSE. These results will also be published in newspapers as required by SEBI regulations.
Board Meeting Details
The Board Meeting commenced at 02:00 P.M. and concluded at 06:00 P.M. on November 4, 2026.
Consolidated Financial Highlights (Unaudited)
For the Quarter Ended September 30, 2026:
- Total Income: ₹13,630 million
- Total Expenses: ₹12,703 million
- Profit Before Tax: ₹1,055 million
- Profit After Tax: ₹746 million
For the Half Year Ended September 30, 2026:
- Total Income: ₹25,589 million
- Total Expenses: ₹24,106 million
- Profit Before Tax: ₹1,621 million
- Profit After Tax: ₹1,120 million
Standalone Financial Highlights (Unaudited)
For the Quarter Ended September 30, 2026:
- Total Income: ₹5,521 million
- Total Expenses: ₹4,420 million
- Profit Before Tax: ₹1,233 million
- Profit After Tax: ₹929 million
For the Half Year Ended September 30, 2026:
- Total Income: ₹10,664 million
- Total Expenses: ₹8,675 million
- Profit Before Tax: ₹2,121 million
- Profit After Tax: ₹1,594 million
Source: BSE
